Latest Methylphenidate Stories
A new long term study has found that children taking medication for attention deficit disorder received higher scores on tests than those who did not take ADHD medication.
Study shows Clonicel(R) and stimulants combined provide greater improvement in symptoms than stimulants alone DURHAM, N.C., April 23 /PRNewswire/ -- Addrenex Pharmaceuticals, Inc.
TITUSVILLE, N.J., April 22 /PRNewswire/ -- Although Attention Deficit Hyperactivity Disorder (ADHD) is a condition commonly thought of as only affecting children, for nearly 9 million adults in the United States, ADHD is very much a reality.
TITUSVILLE, N.J., March 31 /PRNewswire/ -- The U.S. District Court for the District of Delaware has rendered a decision in the patent litigation between Alza Corporation, McNeil-PPC, Inc. and Andrx Pharmaceuticals LLC.
PHILADELPHIA, March 20 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced today a voluntary market withdrawal/recall of thirty-nine (39) lots of the ADHD patch DAYTRANA (the lots of DAYTRANA patches affected by this action are listed below).
A small government study suggests that the narcolepsy drug modafinil â€” a so-called "smart drug" increasingly being used to enhance cognitive abilities â€” may be more addictive than doctors thought.
DUBLIN, March 16 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that it has decided to withdraw the European Marketing Authorization Application (MAA) for DAYTRANA(TM) (methylphenidate transdermal system) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).
Cocaine use can have toxic effects on brain cells (neurons) that produce dopamine, say experts at Baylor College of Medicine in Houston in a report that appears today in the journal Psychiatry Research.
PHILADELPHIA and DUBLIN, February 20 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that it has signed an agreement with UCB to acquire the worldwide rights to EQUASYM(R) IR and XL (methylphenidate hydrochloride) (excluding the USA, Canada and Barbados) used for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). EQUASYM XL is approved and marketed in 10 countries (outside the USA, Canada, and...
Drugs prescribed for attention deficit hyperactivity disorder can induce hallucinations even when taken as directed, US government researchers announced on Monday.
- To swell, as grain or wood with water.